Neuroene Therapeutics Co-Founder and CEO Sherine Chan, Ph.D., joins Rich Bendis on BioTalk to discuss winning the 7th Annual BioHealth Capital Region Crab Trap, their drug discovery platform and being located at JLABS @ Washington, DC.
Listen now via Google bit.ly/3D5tm9O, apple.co/3eGzXy7, or Spotify spoti.fi/3D6lgOx.
B
altimore’s Vita Therapeutics announced the completion of a $31 million series B funding round on Wednesday, propelling the cell therapy company toward a clinical trial and the development of new treatments for rare diseases.
Image: Vita Therapeutics, led by CEO Douglas Falk, recently completed a $31 million series B funding round. – Douglas Falk
“The 2022 venture capital market” is nearly a misnomer, as each quarter that passes seems to bring with it a new normal for startup investment. The pace of quarterly change in how venture investors are disbursing capital is making full-year numbers almost misleading.
The change inside of 2022, in other words, may at times mask just how much things have been evolving more recently; January and February feel like years ago in startup time, not merely a few quarters back.
Image: https://techcrunch.com/
We are so thankful for our Entrepreneurs-in-Residence (EIRs), who provide free business development guidance and counsel to assist #SmallBiz awardees with progress toward #commercialization objectives and ensuring success in the market. Each EIR brings unique expertise and experience from the field. Learn more and connect with an EIR today: https://bit.ly/3Ov55gH #Entrepreneur
Venture-capital firms are jumping into the stock market, buying up battered shares in publicly traded tech companies at a time when they are investing less in the startups that have long been their focus.
Some major venture firms including Accel and Lightspeed Venture Partners have purchased more stocks of companies they first backed as startups this year, defying the industry norm of selling those shares soon after public listings.
Image: One of Amplitude’s largest shareholders when the data-analytics firm went public was Sequoia Capital.
PHOTO: ANDREW KELLY/ASSOCIATED PRESS
Oct 10 (Reuters) – California-based diagnostics company Bio-Rad Laboratories (BIO.N) is in talks to merge with Qiagen NV (QIA.DE), the Wall Street Journal reported on Monday, citing people familiar with the matter.
Talks between the two companies have been going on for a while but an agreement is unlikely for another few weeks, the report said.
U.S-listed shares of Qiagen rose 8% while Bio-Rad fell nearly 10% after the report.
Biotech and life sciences companies can benefit from partnering with the federal government in many ways, from funding to increased access to resources and manufacturing. But lesser-known than its counterparts at the National Institute of Health and National Cancer Institute is the Biomedical Advanced Research and Development Authority, or BARDA.
Image: https://biobuzz.io/
What does the Zulu word “ubuntu” have to do with a successful science and tech fund at Maryland’s TEDCO? To start, it’s been a guiding force for that fund’s leader.
The Maryland Technology Development Corporation (TEDCO) has an important mission in Maryland: “enhance economic empowerment by fostering an inclusive and entrepreneurial innovation ecosystem. Identify, invest in, and help grow technology companies in Maryland.”
Image: https://www.tedcomd.com/about-tedco/staff/arti-santhanam-phd
Oct 12, 2022
GAITHERSBURG, Md., Oct. 12, 2022 /PRNewswire/ — Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today presented data from the Phase 3 PREVENT-19 trial and Study 307 (Lot Consistency) at the World Vaccine Congress Europe 2022. PREVENT-19 data in both adults aged 18 and older and adolescents aged 12 through 17 showed the prototype Novavax COVID-19 vaccine (NVX-CoV2373) achieved its pre-specified immunologic endpoint. Study 307 (Lot Consistency) met its primary endpoint, showing that three lots of the Novavax COVID-19 vaccine tested as a heterologous booster induced consistent immune responses in previously vaccinated adults aged 18 to 49.
WASHINGTON–(BUSINESS WIRE)–The Biotechnology Innovation Organization (BIO) – the world’s largest science and public advocacy organization, representing 1,000 members — announced today that Rachel King, co-founder and former CEO of GlycoMimetics, Inc., has agreed to serve as interim President and CEO. King’s appointment follows Dr. Michelle McMurry-Heath stepping down as President and CEO to serve as an Advisor to the Executive Committee of the BIO Board of Directors. The organization is searching for a full-time successor.
